Please provide your email address to receive an email when new articles are posted on . Transcranial magnetic stimulation targets the central executive network. 80% of patients responded by 20 ...
GlobalData on MSN
FDA clears Zeta Surgical’s robotic TMS navigation system
Transcranial magnetic stimulation (TMS) is primarily used as an alternative or add-on depression treatment and for addressing ...
Nearly half of individuals diagnosed with PTSD also meet criteria for major depressive disorder (MDD), making comorbid ...
A recent meta-analysis published in the journal eLife provides evidence that applying noninvasive magnetic stimulation to a ...
BURLINGTON, Mass. and JERUSALEM, Sept. 16, 2025 (GLOBE NEWSWIRE) -- BrainsWay Ltd. (NASDAQ & TASE: BWAY) (“BrainsWay” or the “Company”), a global leader in advanced noninvasive neurostimulation ...
Advances in neuromodulation are challenging conventional approaches and expanding non‑drug treatment options for ...
Preliminary Data Analysis Reveals Over 80% Remission Rate One Year after Accelerated Deep TMS Treatment, with Decline in Severe Functional Impairment from 85% to 0%BURLINGTON, Mass. and JERUSALEM, ...
Deep Transcranial Magnetic Stimulation (dTMS) is a revolutionary depression treatment. It has been FDA-cleared to safely and effectively treat major depressive disorder through BrainsWay’s patented ...
Nearly one in four American adults lives with a mental health condition. That’s more than 60 million people — veterans, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results